Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as rhuMAb VEGF (telbermin), rhuMAb VEGF (Bevacizumab)
rhuMAb VEGF · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| rhuMAb VEGF (Bevacizumab) | DRUG | - |
| rhuMAb VEGF (telbermin) | DRUG | - |
Inclusion Criteria: * Written informed consent * Women \>=18 years of age * Histologically confirmed carcinoma of the breast with metastatic disease that is currently progressing; in subjects who present with metastatic disease, cytologic confirmation is permissible * Prior administration of one or...
Top 20 of 87 competitors
rhuMAb VEGF is an investigational monoclonal antibody developed by Roche Holding AG (ticker RHHBY). It has been studied in Phase 3 clinical development for breast cancer and in earlier development for chronic diabetic foot ulcers. It is not described as approved, and it remains an investigational agent in clinical research.
rhuMAb VEGF has been studied in breast cancer as a treatment given in combination with chemotherapy in patients with previously treated disease. That research was conducted as a Phase 3 trial. The program is investigational, and the available information does not establish approval for this or any indication.
rhuMAb VEGF is a monoclonal antibody, and its name reflects an antibody (the -mab suffix) directed at vascular endothelial growth factor. Antibodies in this class bind VEGF, the signaling protein involved in blood vessel formation. The supplied information identifies the antibody class and VEGF-directed naming but does not detail downstream pharmacology.
Roche Holding AG is the developer of rhuMAb VEGF. Roche trades on the OTC market under the ticker RHHBY. The company has sponsored clinical research of the antibody in breast cancer and in chronic diabetic foot ulcers.
rhuMAb VEGF has reached Phase 3 in breast cancer, where it was studied in combination with chemotherapy in previously treated patients. A separate topical formulation was studied in a Phase 1 trial in chronic diabetic foot ulcers. The agent is investigational and is not described as approved.
Two completed studies are identified. NCT00109239 was a Phase 3 trial of rhuMAb VEGF (bevacizumab) with chemotherapy in previously treated breast cancer. NCT00069446 was a Phase 1 trial of topical recombinant human VEGF (telbermin) for healing chronic diabetic foot ulcers, enrolling 50 participants.
rhuMAb VEGF has been referenced under two related names: telbermin, used for the topical recombinant human VEGF studied in diabetic foot ulcers, and bevacizumab, used for the antibody studied in breast cancer. These names appear in the trial titles for the two completed studies of the program.